Hvorfor er resultater fra organisert mammografiscreening så vanskelig å tolke?

Tidsskrift for den Norske Laegeforening

Volumn 134, Issue 11, 2014, Pages 1124-1126

  Falk, Ragnhild Sørum ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; MAMMOGRAPHY; MASS SCREENING; METHODOLOGY; NORWAY; PROGRAM EVALUATION; RADIOGRAPHY;

BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; NORWAY; PROGRAM EVALUATION;

EID: 84903648234     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.13.1655     Document Type: Note

References (21)

1. Hofvind S, Geller B, Vacek PM et al. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol 2007; 22: 447-55.
2. Day NE. Overdiagnosis and breast cancer screening. Breast Cancer Res 2005; 7: 228-9.
3. Marmot MG, Altman DG, Cameron DA et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013; 108: 2205-40.
4. Duffy SW, Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res 2013; 15: R41.
5. de Gelder R, Heijnsdijk EA, van Ravesteyn NT et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011; 33: 111-21.
6. Puliti D, Duffy SW, Miccinesi G et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012; 19 (suppl 1): 42-56.
7. Hofvind S. Organisert mammografiscreening-flere fordeler enn ulemper. Tidsskr Nor Legeforen 2013; 133: 619-20.
8. Zahl PH. Informasjonen om mammografiscreening er ikke nøytral. Tidsskr Nor Legeforen 2013; 133: 1557-8.
9. Duffy SW, Smith RA. More on screening mammography. N Engl J Med 2011; 364: 283.
10. Haldorsen T, Tretli S, Ursin G. Overdiagnosis of invasive breast cancer due to mammography screening. Ann Intern Med 2012; 157: 220.
11. Tretli S, Ursin G. Overdiagnostikk ved mammografiscreening. Tidsskr Nor Legeforen 2012; 132: 1206.
12. Benestad HB, Laake P. Forskning: Metode og planlegging. I: Benestad HB, Laake P, red. Forskningsmetode i medisin og biofag. Oslo: Gyldendal Akademisk, 2004: 83-113.
13. Kalager M, Zelen M, Langmark F et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203-10.
14. Olsen AH, Lynge E, Njor SH et al. Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer 2013; 132: 208-14.
15. Hofvind S, Ursin G, Tretli S et al. Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer 2013; 119: 3106-12.
16. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004; 328: 921-4.
17. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587.
18. Zahl PH, Mæhlen J. Overdiagnostikk av brystkreft etter 14 år med mammografiscreening. Tidsskr Nor Legeforen 2012; 132: 414-7.
19. Kalager M, Adami HO, Bretthauer M et al. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491-9.
20. Falk RS, Hofvind S, Skaane P et al. Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer 2013; 133: 705-12.
21. Statistisk sentralbyrå. Statistikkbanken. Befolkning. Folkemengden. Tabell 07459: Folkemengde etter kjønn og ettårig alder. www.ssb.no/ statistikkbanken/selecttable/hovedtabellHjem. asp?KortNavnWeb=folkemengde&CMS SubjectArea=befolkning&checked=true (10.10.2013).